Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Complement C1q does not bind monomeric beta-amyloid

S W Snyder1, G T Wang, L Barrett

  • 1Pharmaceutical Products Division, Abbott Laboratories, Abbott Park, Illinois 60064.

Experimental Neurology
|July 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Large-scale analysis of expressed genes from the leaf of oilseed rape (Brassica napus L.).

Plant cell reports·2019
Same author

Anticarcinogenic effect of indole-3-carbinol (I3C) on human hepatocellular carcinoma SNU449 cells.

Human & experimental toxicology·2018
Same author

Phase I/II clinical trial to assess safety and efficacy of intratumoral and subcutaneous injection of HVJ-E in castration-resistant prostate cancer patients.

Cancer gene therapy·2017
Same author

Effects of ABCB1 Genetic Polymorphism on the Oral Absorption of Losartan.

Clinical therapeutics·2016
Same author

Effects of Genetic Polymorphism of Cyp2c19 on the Pharmacokinetics of Zolpidem.

Clinical therapeutics·2016
Same author

Frequency and risk factors of drug-induced liver injury during treatment of multidrug-resistant tuberculosis.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2016
Same journal

Opportunities and challenges for the application of single-cell RNA sequencing and spatial transcriptomics in ischemic stroke.

Experimental neurology·2026
Same journal

Behavioral and functional characterization of early-stage Parkinson's disease models reveals attentional deficits and circuit-level connectivity alterations.

Experimental neurology·2026
Same journal

Neuropathological and functional impact of astrocyte-derived extracellular vesicles in an aged model of Alzheimer's disease.

Experimental neurology·2026
Same journal

PI3K/Akt pathway in ischemic stroke: A central regulator of neuronal survival and repair.

Experimental neurology·2026
Same journal

Hepatokines and stellakines in liver and neurological diseases: The liver-brain axis.

Experimental neurology·2026
Same journal

Structural dynamics of α-Synuclein: Multi-scale imaging insights into pathological progression across Synucleinopathies.

Experimental neurology·2026
See all related articles

Monomeric beta-amyloid does not bind to complement C1q, suggesting it does not initiate the classical complement pathway in Alzheimer's disease. This finding impacts understanding of amyloid's role in neuroinflammation.

Area of Science:

  • Biochemistry
  • Immunology
  • Neuroscience

Background:

  • Alzheimer's disease is linked to amyloid-beta (Aβ) and complement system activation.
  • C1q is the initial recognition molecule of the classical complement cascade.

Purpose of the Study:

  • To investigate the binding interaction between monomeric beta-amyloid and C1q.
  • To determine if beta-amyloid initiates complement activation via the classical pathway.

Main Methods:

  • Utilized hydrodynamic and spectroscopic methods to analyze binding.
  • Employed purified synthetic beta-amyloid 1-40, with and without spectroscopic probes.
  • Assessed C1q's structural integrity and binding capacity to IgM.

Main Results:

Related Experiment Videos

  • Beta-amyloid 1-40 existed as a monomer in solution under experimental conditions.
  • C1q maintained its quaternary structure and IgM-binding ability.
  • Monomeric beta-amyloid showed no binding or interaction with C1q below approximately 100 microM.

Conclusions:

  • Monomeric beta-amyloid is unlikely to be responsible for activating the classical complement pathway.
  • The study suggests alternative mechanisms for complement involvement in Alzheimer's disease pathogenesis.